SQNMF 財務： Sequana Medical NV AI 分析

首頁

股票

SQNMF

財務狀況

SQNMF 財務

Sequana Medical NV

0%

$0

收盤價：Mar 24, 16:00:00 GMT-4

$1.22

0%

$0

盤後：Mar 24, 20:00:00 GMT-4

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

SQNMF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	0	0	0	0	0	0
營收年增率 (YoY)	--	--	--	--	--	--
營收成本	3	3	4	3	2	1
毛利	-3	-3	-4	-2	-2	0
銷售、一般及管理費用	8	7	8	8	7	6
研發	--	--	--	--	--	--
營業費用	13	14	24	25	20	16
其他非營業收入 (費用)	0	0	0	0	--	0
稅前淨利	-51	-44	-32	-30	-23	-18
所得稅費用	0	0	0	0	0	0
淨利	-51	-44	-32	-30	-23	-19
淨利成長	89%	38%	7%	30%	21%	36%
稀釋後流通股數	52.41	36.74	26.77	22.76	18.21	15.31
股數年變動 (YoY)	46%	37%	18%	25%	19%	25%
每股盈餘 (稀釋)	-0.98	-1.21	-1.21	-1.35	-1.29	-1.24
每股盈餘成長率	31%	0%	-10%	4%	4%	2%
自由現金流	-17	-20	-29	-28	-23	-17
每股自由現金流	--	--	--	--	--	--
毛利率	0%	0%	0%	0%	0%	0%
營業利益率	0%	0%	0%	0%	0%	0%
淨利率	0%	0%	0%	0%	0%	0%
自由現金流利潤率	0%	0%	0%	0%	0%	0%
EBITDA	-16	-18	-28	-28	-22	-17
EBITDA 利潤率	0%	0%	0%	0%	0%	0%
EBITDA 中的折舊與攤銷	1	0	0	0	0	0
EBIT	-17	-18	-28	-28	-22	-17
EBIT 利潤率	0%	0%	0%	0%	0%	0%
有效稅率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Sequana Medical NV 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），Sequana Medical NV 的總資產為 $9，淨損失為 $-44

SQNMF 的關鍵財務比率是什麼？



Sequana Medical NV 的流動比率為 0.16，淨利潤率為 0，每股銷售為 $0。

Sequana Medical NV 的收入按細分市場或地理位置如何劃分？



Sequana Medical NV 最大收入來源為 Medical Device，在最近的收益報告中收入為 712,173。就地區而言，Germany 是 Sequana Medical NV 的主要市場，收入為 553,500。

Sequana Medical NV 是否盈利？



無，根據最新的財務報表，Sequana Medical NV 的淨損失為 $-44

Sequana Medical NV 有負債嗎？



是的，Sequana Medical NV 的負債為 54

Sequana Medical NV 的流通股有多少？



Sequana Medical NV 的總流通股為 44.43

關鍵數據

前收市價

開盤價

當日範圍

52週區間

$0.78 - $3

交易量

平均成交量

350

股息收益率

每股盈餘 (TTM)

市值

$93.5M

什麼是 SEQUANA MEDICAL NV？

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

功能特性

資源